Gene modification strategies using AO-mediated exon skipping and CRISPR/Cas9 as potential therapies for Duchenne muscular dystrophy patients. (2020)

First Author: Solberg MH
Attributed to:  FUTURE TARGETED HEALTHCARE MANUFACTURING HUB funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1049/enb.2020.0017

PubMed Identifier: 36968157

Publication URI: http://europepmc.org/abstract/MED/36968157

Type: Journal Article/Review

Volume: 4

Parent Publication: Engineering biology

Issue: 3

ISSN: 2398-6182